卵巢恶性肿瘤组织中uPA及其PAI-1表达的临床意义

A STUDY OF THE RELATIONSHIP BETWEEN THE EXPRESSION OF PLASMINOGEN ACTIVATOR,PLASMINOGEN ACTIVATOR INHIBITORS AND INVASION AND METASTASIS IN OVARIAN CARCINOMA

目的:探讨卵巢恶性肿瘤组织中尿型纤溶酶原激活因子(uPA)及其1型抑制因子(PAI-1)表达的临床意义。方法:采用免疫组化SABC法检测uPA、PAI-1在40例卵巢恶性肿瘤、20例卵巢良性肿瘤及20例正常卵巢组织中的表达情况并分析其与临床病理因素及预后的相关性。结果:①uPA、PAI-1在卵巢恶性肿瘤组织中的阳性表达率明显高于卵巢良性肿瘤组织和正常组织(P<0.05)。②在临床分期Ⅲ～Ⅳ期者其卵巢恶性肿瘤组织中uPA、PAI-1阳性表达率明显高于Ⅰ～Ⅱ期(P<0.05)。③uPA、PAI-1表达阳性者,平均生存时间分别均为29.32、31.78个月,明显低于uPA、PAI-1表达阴性者的49.0、52.23个月(P<0.05)。Cox模型分析显示PAI-1表达为影响卵巢癌预后的独立因子。结论:uPA、PAI-1表达与卵巢恶性肿瘤的发生及侵袭、转移相关,并与卵巢恶性肿瘤的不良预后关系密切。

Objective： To explore the clinical-pathologic parameters on expression of plasminogen activator （uPA）, plasminogen activator inhibitors （PAI-1） in ovarian cancer. Methods： The Streptavidin-Peroxidase immunnohistochemistry method was used to determine the expression of uPA, PAI-1 in 40 cases of ovarian malignant, 20 cases of ovarian benign neoplasm, and 20 cases of normal control, and the relationship of expression of uPA,PAI-1 and clinical-pathologic parameters in ovarian neoplasm. Result： （1）The positive expression rates of uPA,PAI-1 in ovarian malignancy were significantly higher than those in ovarian benign neoplasm and normal control（ P d0.05）. （2）The positive expression rates of uPA,PAI-1 in the patients with low differentiation grade, late stage, omentum involvement（＋） and residual tumor volume〉2 cm were also significantly higher than differentiation grade, early stage, omentum involvement（-） and residual tumor volume〈2 cm. （3）The cumulative survival time of patients with positive expression of uPA,PAI-1 was longer than that without expression（ P〈0.01）. The analysis of Cox model showed that expression of PAI-1 in ovarian malignancy was also independent prognosis factor for ovarian cancer. Conclusion： The uPA,PAI-1 would play an importation role in invasion and metastasis of ovarian malignancy, and also was related with poor prognosis in ovarian cancer.